» Articles » PMID: 34768479

Functionally Heterogenous Macrophage Subsets in the Pathogenesis of Giant Cell Arteritis: Novel Targets for Disease Monitoring and Treatment

Overview
Journal J Clin Med
Specialty General Medicine
Date 2021 Nov 13
PMID 34768479
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Giant cell arteritis (GCA) is a granulomatous large-vessel vasculitis that affects adults above 50 years of age. In GCA, circulating monocytes are recruited to the inflamed arteries. With cues from the vascular microenvironment, they differentiate into macrophages and play important roles in the pathogenesis of GCA via pro-inflammatory cytokine production and vascular remodeling. However, a deeper understanding of macrophage heterogeneity in GCA pathogenesis is needed to assist the development of novel diagnostic tools and targeted therapies. Here, we review the current knowledge on macrophage heterogeneity and diverse functions of macrophage subsets in the pathogenesis of GCA. We next discuss the possibility to exploit their heterogeneity as a source of novel biomarkers and as targets for nuclear imaging. Finally, we discuss novel macrophage-targeted therapies and future directions for targeting these cells in GCA.

Citing Articles

The innate face of Giant Cell Arteritis: Insight into cellular and molecular innate immunity pathways to unravel new possible biomarkers of disease.

Rizzo C, Barbera L, Miceli G, Tuttolomondo A, Guggino G Front Mol Med. 2024; 2:933161.

PMID: 39086970 PMC: 11285707. DOI: 10.3389/fmmed.2022.933161.


Giant Cell Arteritis: Updates and Controversies.

Yu E, Chang J Front Ophthalmol (Lausanne). 2024; 2:848861.

PMID: 38983551 PMC: 11182101. DOI: 10.3389/fopht.2022.848861.


Predominance of T-bet-positive Th1 cells in infiltrating T-lymphocytes in most of active arteritis lesions of giant cell arteritis.

Satomi H, Kobayashi M, Ito I, Asano K, Makino M, Kawaguchi K Virchows Arch. 2024; 486(2):267-275.

PMID: 38478104 DOI: 10.1007/s00428-024-03776-x.


The Contribution of Innate Immunity in Large-Vessel Vasculitis: Detangling New Pathomechanisms beyond the Onset of Vascular Inflammation.

Barbera L, Rizzo C, Camarda F, Miceli G, Tuttolomondo A, Guggino G Cells. 2024; 13(3.

PMID: 38334663 PMC: 10854891. DOI: 10.3390/cells13030271.


Giant Cell Arteritis: Advances in Understanding Pathogenesis and Implications for Clinical Practice.

Paroli M, Caccavale R, Accapezzato D Cells. 2024; 13(3.

PMID: 38334659 PMC: 10855045. DOI: 10.3390/cells13030267.


References
1.
Bosco M . Macrophage polarization: Reaching across the aisle?. J Allergy Clin Immunol. 2019; 143(4):1348-1350. DOI: 10.1016/j.jaci.2018.12.995. View

2.
Wilson J, Sarsour K, Collinson N, Tuckwell K, Musselman D, Klearman M . Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis. Semin Arthritis Rheum. 2017; 46(6):819-827. DOI: 10.1016/j.semarthrit.2016.11.006. View

3.
Tomita T, Imakawa K . Matrix metalloproteinases and tissue inhibitors of metalloproteinases in giant cell arteritis: an immunocytochemical study. Pathology. 1998; 30(1):40-50. DOI: 10.1080/00313029800169655. View

4.
Franceschi C, Campisi J . Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014; 69 Suppl 1:S4-9. DOI: 10.1093/gerona/glu057. View

5.
Schmidt W, Moll A, Seifert A, Schicke B, Gromnica-Ihle E, Krause A . Prognosis of large-vessel giant cell arteritis. Rheumatology (Oxford). 2008; 47(9):1406-8. DOI: 10.1093/rheumatology/ken258. View